
Guardant Health Tests to Become Available on OncoEMR Platform From Flatiron Health Used by 2,000 Oncologists
10-31-23 (by: Scott Gleason) Guardant Health and Flatiron Health have joined forces to simplify access to critical genomic data in oncology patient care. Guardant Health’s comprehensive genomic profiling tests will be integrated into Flatiron Health’s OncoEMR®, a cloud-based electronic medical record (EMR) system. Over 2,000 clinicians in the Flatiron network, spread across more than 800 community-based cancer care locations in the U.S., will now have streamlined access to Guardant Health’s tests. This integration allows clinicians to easily order tests, track real-time status updates, and receive test results directly in patient records. By enhancing the workflow for physicians, this initiative aims to expedite informed decision-making regarding personalized treatment plans for cancer patients. Beta tests of the integration yielded over 75% utilization compared to traditional ordering methods, making it a promising development in the fight against cancer. The full integration will be rolled out to the entire OncoEMR network over the coming months, offering a comprehensive suite of advanced blood and tissue tests for cancer patients.
Flatiron Health was acquired in 2018 by the Roche Group, owner of Guardant Health competitor Foundation Medicine. The company’s OncoEMR® is an advanced oncology Electronic Health Record (EHR) software designed to empower community oncologists with intuitive and efficient tools for patient care. OncoEMR® provides an array of features to enhance patient care, including the OncoAir™ mobile app, embedded clinical content, a user-friendly patient portal, integrated research tools, and compatibility with various healthcare tools and programs. OncoEMR® has more than 1,800 live interfaces with 150+ healthcare vendors and products.